A remote monitoring system, piloted by two nurses and an application, has just proven itself.
- According to the National Cancer Institute (INCa), the number of new cases of cancer for 2018 in metropolitan France is estimated at 382,000.
- For 30 years, the overall number of new cases of cancer in France has been increasing every year.
The CAPRI remote monitoring device developed at Gustave Roussy has scientifically demonstrated its contribution to patients living with cancer undergoing oral treatment, according to a new study clinic published in Nature Medicine.
“The first stone of digitization”
“These results pave the way for digital follow-up of these patients, and position Gustave Roussy as one of the leaders and pioneers on the importance of using digital innovation to ensure better safety and quality of follow-up for patients treated for cancer” , believe the authors of the research. “More generally, they lay the foundation stone for the generalized digitization of patient pathways as defined by Gustave Roussy’s 2030 institutional strategic project”, they add.
Many cancer patients require long-term care, which today often consists of oral therapies. The objective of Gustave Roussy’s phase IIII randomized clinical study was to determine whether an intervention combining a remote monitoring system (piloted by two nurses and an application in addition to usual care) improved patient care compared to conventional follow-up over a period of 6 months.
Fewer hospitalizations
At the end of the tests, out of 559 evaluable patients, the relative intensity dose* was statistically significantly higher in the arm with digital monitoring (93.4%) compared to conventional monitoring (89.4%). The study also measured the usefulness of the CAPRI device with patients with the PACIC score (Patient Assessment of Chronic illness care / Quality of care perceived by a patient with chronic illness), which was higher in the device. digital monitoring than in conventional monitoring. CAPRI also made it possible to reduce the duration of hospitalization during treatment (2.82 against 4.44 days), as well as the use of emergencies (15.1% against 22) and the most severe toxicities linked to the treatment ( 27.6% versus 36.9%).
“These results scientifically and significantly demonstrate that remote digital monitoring of patients with all types of advanced-stage solid tumors and treated with oral anticancer drugs jointly improves the quality of care and the experience of these patients, while reducing hospital visits, and that it is possible to combine digital technology and humanity”, conclude the French researchers.
*The intensity of treatment dose actually received by the patient.